Form 4 Filing for Alkermes plc.

This filing details transactions made by Craig C. Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc. On July 1, 2026, Hopkinson acquired 5,000 ordinary shares through the exercise of employee stock options at a price of $19.34 per share, increasing his post-transaction holdings to 82,389 shares. Concurrently, he disposed of 8,300 shares at a weighted average price of $51.4613 and an additional 700 shares at a weighted average price of $52.1314. These transactions were executed under Rule 10b5-1 trading plans. Following these sales, Hopkinson’s post-transaction share count was reduced to 73,389. The filing also notes the disposal of 5,000 vested options with a strike price of $19.34, leaving 1,356 options outstanding.